A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2026-05-01

Summary

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with advanced head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and cholangiocarcinoma.

The main questions it aims to answer are:

• is the new drug plus standard treatment safe and tolerable

• is the new drug plus standard treatment more effective than standard treatment

• Phase: Phase 2

Details

• Lead Sponsor: Lisata Therapeutics, Inc.
• Treatments: Cisplatin; Docetaxel; Durvalumab; Gemcitabine; Paclitaxel